Lynch Regenerative Medicine, LLC

FDA Authorizes Lynch Regenerative Medicine's IND for a Phase IIb Clinical Trial for Injection of rhPDGF-BB for Treatment of Infraorbital Hollowing

Multi-center, randomized controlled study will evaluate the safety and preliminary efficacy of investigational injectable rhPDGF-BB in up to 75…